PMPhilippe Meersseman

Philippe Meersseman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philippe Meersseman has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic Determinants in Patients With Cirrhosis and Septic Shock: Beyond Relative Adrenal Insufficiency

    by Philippe Meersseman, Alexander Wilmer, Javier Fernandez


  • Open Access

    Low‐Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double‐Blind Randomised Placebo‐Controlled Trial

    by Philippe Meersseman, María Hernández‐Tejero, Juan Manuel Diaz, Joost Wauters, Greet Hermans, Fátima Aziz, Helga Ceunen, Veronica Prado, Lies Langouche, Mireya Arteaga, et al.

    Background and Aims: Steroid supplementation remains controversial in septic shock, partly due to the heterogeneity of the populations studied. Cirrhotic patients with sepsis frequently develop relative adrenal insufficiency, showing poor response to vasopressors and poor prognosis. Early administration of low‐dose hydrocortisone might facilitate shock reversal and reduce mortality in this population. Methods: Double‐blind, randomised, placebo‐controlled multicentre trial, enrolling adult cirrhotic patients with septic shock. Patients were assigned to receive i.v. hydrocortisone (100 mg followed by a continuous infusion of 200 mg/24 h) or placebo, for at least 3 days, followed by a tapering period of 3–7 days, depending on the time of shock resolution. Primary endpoint was 28‐day all‐cause mortality. Results: After enrolment of 83 patients the trial was stopped early due to slow inclusions. Most patients required low‐to‐moderate doses of vasopressors. There was no difference in 28‐day mortality (35% vs. 39.5%; p = 0.84) between hydrocortisone and placebo groups. Shock resolution (85% vs. 72.1%; p = 0.25) and days to shock resolution [3 days (2.2–4; IQR) vs. 4 (2–7.5; IQR)] were also similar between groups. More patients receiving placebo died of refractory shock (47.6% vs. 8.7%). No significant differences between treatment arms were observed in shock relapse, new shock episodes or bacterial or fungal superinfections during hospital stay. Hypo‐ and hyperglycaemias were more frequent in the hydrocortisone arm. Severity of ACLF at inclusion and inadequacy of empirical antibiotic therapy (HR = 6.40; 95% CI: 3.21–12.79) independently predicted 28‐day mortality. Conclusions: Supplemental hydrocortisone did not improve short‐term survival in cirrhotic patients with septic shock requiring low‐to‐moderate doses of vasopressors. Trial Registration: S‐number University Hospitals Leuven, Belgium: S55168; EUDRACT: 2010–024273‐38; Clinicaltrials.gov id: NCT02602210


  • Inspiratory effort and respiratory muscle activation during different breathing conditions in patients with weaning difficulties: An exploratory study

    by Diego Poddighe, Marine Van Hollebeke, Beatrix Clerckx, Luc Janssens, Geert Molenberghs, Lisa Van Dyck, Jan Muller, Jan Gunst, Philippe Meersseman, Marijke Peetermans, et al.


  • Open Access

    Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis

    by Simon Feys, Martina Cardinali-Benigni, Hanne Moon Lauwers, Cato Jacobs, Annelies Stevaert, Samuel M. Gonçalves, Cristina Cunha, Yves Debaveye, Greet Hermans, Jannes Heylen, et al.

    Rationale: The influence of the lung bacterial microbiome, including potential pathogens, in patients with influenza-associated pulmonary aspergillosis (IAPA) or coronavirus disease (COVID-19)–associated pulmonary aspergillosis (CAPA) has yet to be explored. Objectives: To explore the composition of the lung bacterial microbiome and its association with viral and fungal infection, immunity, and outcome in severe influenza versus COVID-19 with or without aspergillosis. Methods: We performed a retrospective study in mechanically ventilated patients with influenza and COVID-19 with or without invasive aspergillosis in whom BAL for bacterial culture (with or without PCR) was obtained within 2 weeks after ICU admission. In addition, 16S rRNA gene sequencing data and viral and bacterial load of BAL samples from a subset of these patients, and of patients requiring noninvasive ventilation, were analyzed. We integrated 16S rRNA gene sequencing data with existing immune parameter datasets. Measurements and Main Results: Potential bacterial pathogens were detected in 20% (28/142) of patients with influenza and 37% (104/281) of patients with COVID-19, whereas aspergillosis was detected in 38% (54/142) of patients with influenza and 31% (86/281) of patients with COVID-19. A significant association between bacterial pathogens in BAL fluid and 90-day mortality was found only in patients with influenza, particularly patients with IAPA. Patients with COVID-19, but not patients with influenza, showed increased proinflammatory pulmonary cytokine responses to bacterial pathogens. Conclusions: Aspergillosis is more frequently detected in the lungs of patients with severe influenza than bacterial pathogens. Detection of bacterial pathogens associates with worse outcome in patients with influenza, particularly in those with IAPA, but not in patients with COVID-19. The immunological dynamics of tripartite viral–fungal–bacterial interactions deserve further investigation.


  • Open Access

    The Toulouse algorithm identifies patients with increased risk of cardiac decompensation only in patients with TIPS for refractory ascites

    by Emma Vanderschueren, Youri Bekhuis, Jan Clerick, Jappe Decock, Philippe Meersseman, Alexander Wilmer, Eveline Claus, Lawrence Bonne, Guido Claessen, Chris Verslype, et al.


  • Open Access

    Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure

    by Rita Feio-Azevedo, Markus Boesch, Silvia Radenkovic, Lukas van Melkebeke, Lena Smets, Marie Wallays, Bram Boeckx, Gino Philips, Janaíne Prata de Oliveira, Mohammad Ghorbani, et al.

    Background and Aims: Acute-on-chronic liver failure (ACLF) is a complication of cirrhosis characterized by multiple organ failure and high short-term mortality. The pathophysiology of ACLF involves elevated systemic inflammation leading to organ failure, along with immune dysfunction that heightens susceptibility to bacterial infections. However, it is unclear how these aspects are associated with recovery and nonrecovery in ACLF. Approach and Results: Here, we mapped the single-cell transcriptome of circulating immune cells from patients with ACLF and acute decompensated (AD) cirrhosis and healthy individuals. We further interrogate how these findings, as well as immunometabolic and functional profiles, associate with ACLF-recovery (ACLF-R) or nonrecovery (ACLF-NR). Our analysis unveiled 2 distinct states of classical monocytes (cMons). Hereto, ACLF-R cMons were characterized by transcripts associated with immune and stress tolerance, including anti-inflammatory genes such as RETN and LGALS1. Additional metabolomic and functional validation experiments implicated an elevated oxidative phosphorylation metabolic program as well as an impaired ACLF-R cMon functionality. Interestingly, we observed a common stress-induced tolerant state, oxidative phosphorylation program, and blunted activation among lymphoid populations in patients with ACLF-R. Conversely, ACLF-NR cMon featured elevated expression of inflammatory and stress response genes such as VIM, LGALS2, and TREM1, along with blunted metabolic activity and increased functionality. Conclusions: This study identifies distinct immunometabolic cellular states that contribute to disease outcomes in patients with ACLF. Our findings provide valuable insights into the pathogenesis of ACLF, shedding light on factors driving either recovery or nonrecovery phenotypes, which may be harnessed as potential therapeutic targets in the future.


  • Open Access

    Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

    by Marijke Peetermans, Veerle Matheeussen, Cedric Moerman, Fréderic De Rydt, Sabine Thieren, Emily Pollet, Michael Casaer, Benjamin De Backer, Rudi De Paep, Yves Debaveye, et al.


  • Open Access

    Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review

    by Beatrijs Mertens, Omar Elkayal, Erwin Dreesen, Joost Wauters, Philippe Meersseman, Yves Debaveye, Karlien Degezelle, Pieter Vermeersch, Matthias Gijsen, Isabel Spriet

    Effective dosing of isavuconazole in patients supported by extracorporeal membrane oxygenation (ECMO) is important due to the role of isavuconazole as a first-line treatment in patients with influenza- and COVID-19-associated pulmonary aspergillosis. To date, robust pharmacokinetic data in patients supported by ECMO are limited. Therefore, it is unknown whether ECMO independently impacts isavuconazole exposure. We measured isavuconazole plasma concentrations in two patients supported by ECMO and estimated individual pharmacokinetic parameters using non-compartmental analysis and two previously published population pharmacokinetic models. Furthermore, a narrative literature review on isavuconazole exposure in adult patients receiving ECMO was performed. The 24 h areas under the concentration–time curve and trough concentrations of isavuconazole were lower in both patients compared with exposure values published before. In the literature, highly variable isavuconazole concentrations have been documented in patients with ECMO support. The independent effect of ECMO versus critical illness itself on isavuconazole exposure cannot be deduced from our and previously published (case) reports. Pending additional data, therapeutic drug monitoring is recommended in critically ill patients, regardless of ECMO support.


  • Open Access

    The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation

    by Beatrijs Mertens, Joost Wauters, Yves Debaveye, Niels Van Regenmortel, Karlien Degezelle, Philippe Meersseman, Greet Hermans, Christophe Vandenbriele, Ruth Van Daele, Isabel Spriet


  • Open Access

    Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza

    by Seppe Cambier, Mieke Metzemaekers, Ana Carolina de Carvalho, Amber Nooyens, Cato Jacobs, Lore Vanderbeke, Bert Malengier-Devlies, Mieke Gouwy, Elisabeth Heylen, Philippe Meersseman, et al.

    Neutrophils are recognized as important circulating effector cells in the pathophysiology of severe coronavirus disease 2019 (COVID-19). However, their role within the inflamed lungs is incompletely understood. Here, we collected bronchoalveolar lavage (BAL) fluids and parallel blood samples of critically ill COVID-19 patients requiring invasive mechanical ventilation and compared BAL fluid parameters with those of mechanically ventilated patients with influenza, as a non–COVID-19 viral pneumonia cohort. Compared with those of patients with influenza, BAL fluids of patients with COVID-19 contained increased numbers of hyperactivated degranulating neutrophils and elevated concentrations of the cytokines IL-1 β , IL-1RA, IL-17A, TNF- α , and G-CSF; the chemokines CCL7, CXCL1, CXCL8, CXCL11, and CXCL12 α ; and the protease inhibitors elafin, secretory leukocyte protease inhibitor, and tissue inhibitor of metalloproteinases 1. In contrast, α -1 antitrypsin levels and net proteolytic activity were comparable in COVID-19 and influenza BAL fluids. During antibiotic treatment for bacterial coinfections, increased BAL fluid levels of several activating and chemotactic factors for monocytes, lymphocytes, and NK cells were detected in patients with COVID-19 whereas concentrations tended to decrease in patients with influenza, highlighting the persistent immunological response to coinfections in COVID-19. Finally, the high proteolytic activity in COVID-19 lungs suggests considering protease inhibitors as a treatment option.